Objective:To evaluate the clinical efficacy and safety of Xihuang Capsules combined with chemotherapy in the treatment of malignant tumors.Methods:CNKI,CCD,CSPD,CBM,PubMed, Web of Science, and Medline databases were searched comprehensively for randomized controlled trials（RCTs） of Xihuang Capsules combined with chemotherapy for malignant tumors from database inception to June 2020 according to the preset inclusion criteria, followed by Meta-analysis.Results:A total of 395 research articles were initially retrieved, and finally 16 RCTs were included, involving 1 288 samples.The meta-analysis found that Xihuang Capsules combined with chemotherapy could improve the total response rate（RR） and disease control rate（DCR） of gastrointestinal cancers（esophageal cancer, gastric cancer, and colon cancer）,lung cancer, and breast cancer, but the clinical efficacy of cervical cancer was not improved.Due to the limitation of the number of studies, their usage in cervical cancer conclusions should be cautious.In addition, this study also found that Xihuang Capsules combined with chemotherapy could improve the KPS score and immune function indicators such as CD3 + ,CD4 + ,and CD4 + /CD8 + ,and reduce the incidence of decrease in blood platelets and Ⅲ～Ⅳ° white blood cells and liver and kidney damage.However, there was no improvement in the incidence of gastrointestinal reactions, reduction in hemoglobin, and Ⅰ～Ⅱ° white blood cells.Conclusion:Xihuang Capsules combined with chemotherapy can improve the clinical efficacy of patients with malignant tumors and reduce the incidence of liver and kidney damage and thrombocytopenia.The conclusion of this study needs more high-quality RCTs for verification.

李冬云教授认为,多发性骨髓瘤便秘的基本病机为正虚为本,毒瘀为标,虚实夹杂.治疗上注重整体,倡导中西医结合治疗.主张分期辨证论治,善用枳术丸临证加减,治疗前期应解毒祛瘀,顾护胃气;治疗中期应健运脾胃,以补开塞;治疗后期应滋补肝肾,增液行舟.巧用中医外治,控制并发症.同时注重日常调摄,调护情志.审证求机,组方用药,取得了较好的疗效.附验案1 则,加以佐证.

介绍李冬云教授基于祛瘀生新法治疗恶性血液病化疗后骨髓抑制的经验.李冬云认为,恶性血液病化疗后骨髓抑制的基本病机为正虚为本,毒瘀为标,瘀血为病机的主要环节,因虚致瘀、因郁致瘀、毒瘀并存、脾肾亏虚,造成骨髓抑制,病情缠绵,多发变证.李冬云临证以祛瘀生新为治疗大法,通过解毒祛瘀、活血化瘀以祛除体内陈腐瘀血,通过疏肝理气、健脾益肾以促进新血的生成,同时注重患者情志的疏导和饮食的调护,使瘀去气血平,瘀去新血生.

痰瘀相关理论首见于《内经》,基于中医学"津血同源"理论而产生.恶性淋巴瘤(ML)中医学称痰核、恶核、积聚等,临床以无痛性、进行性淋巴组织增生,尤以浅表淋巴结肿大为特点,病程较长,易复发.痰瘀是ML核心病机,应以痰瘀同治为原则,其中包含补气扶正、理气疏肝、脾肾同补、清热解毒4个方面,标本同治,气血同调.

目的 通过网络药理学方法研究夏枯草-半夏治疗弥漫大B细胞淋巴瘤(Diffuse large B-cell lym-phoma,DLBCL)的潜在分子机制.方法 首先利用中药系统药理学数据库和分析平台(Traditional Chinese medi-cine system platform,TCMSP)筛选夏枯草-半夏的活性成分及其对应的靶基因.其次,通过GeneCards、OMIM、TTD、DrugBank等数据库搜索DLBCL的疾病靶点,取交集后得到夏枯草-半夏治疗DLBCL的共同靶标基因,将共同靶标基因导入Cytoscape构建"夏枯草-半夏活性成分-DLBCL靶标基因"关系网络图.再通过PPI网络分析,筛选核心靶基因,进行基因本体论和京都基因与基因组百科全书通路分析.结果 夏枯草-半夏治疗DLBCL的主要活性成分有13种,包括槲皮素、β-谷甾醇、豆甾醇等;其作用的核心靶点包括AKT1、JUN、TP53、MAPK1、TNF等;其主要通过调节PI3K-Akt信号通路、TNF信号通路等信号通路发挥治疗DLBCL的作用.结论 夏枯草-半夏可通过多靶标、多途径发挥辅助治疗DLBCL的作用.

目的:通过网络药理学方法探讨新加良附方治疗胃癌的作用机制.方法:在中药系统药理学数据库与分析平台(TCMSP)中获取高良姜、香附、穿山龙的有效成分及靶蛋白,通过Genecards、OMIM数据库筛选出胃癌的靶点,利用Venn软件获取共同靶点,使用Cytoscape3.7.2进行"化合物-靶点-疾病"的网络图构建.通过String数据库获取蛋白互作网络(PPI),最后进行GO功能、KEGG通路富集分析.结果:从新加良附方中筛选出高良姜素、槲皮素、木犀草素、薯蓣皂苷元等主要有效活性成分,作用于87个胃癌靶点,筛选出AKT1、MYC、CASP3、EGFR等关键靶点,并确定了PI3K-Akt信号通路、p53信号通路、Wnt信号通路等关键代谢信号通路,参与蛋白结合、转录因子活性、酶活性调节、受体活性等过程.结论:新加良附方通过多个靶点、多条通路发挥治疗胃癌的作用.